United States
Include All CSL Behring Country Sites

Patient Assistance

Patient Assistance Contact Information by Product:

If you are currently taking one of the following products, you can call the Patient Assistance program at the number below:

Hizentra® Immune Globulin Subcutaneous (Human):
1-877-355-IGIQ (4447)

Privigen® Immune Globulin Intravenous (Human):
1-877-355-IGIQ (4447)

Carimune® Nanofiltered Immune Globulin Intravenous (Human):
1-877-355-IGIQ (4447)

Berinert® C1 Esterase Inhibitor (Human):

Zemaira® alpha1-proteinase inhibitor (Human):

Afstyla® Antihemophilic Factor (Recombinant), Single Chain:

Idelvion® Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP):

Humate P® Antihemophilic Factor/von Willebrand Factor Complex (Human):

Helixate® FS Antihemophilic Factor (Recombinant):

For all other CSL Behring products or questions regarding the Patient Assistance Program:

Main Phone Number:
1-844-PAP-CSLB (727-2752)

At CSL Behring, we are passionate about meeting the needs of our customers and are committed to helping patients get access to our medicines regardless of their financial situation.

About the CSL Behring Patient Assistance ProgramSM

The CSL Behring Patient Assistance Program provides access to CSL Behring therapies for qualified patients who are uninsured or underinsured.

If you or someone you care for has been prescribed a CSL Behring therapy but does not have insurance or their product is not covered by their current insurance carrier, we may be able to help.

You can request help by calling a CSL Behring Care Coordinator at the Patient Assistance Program main number or at the specific product numbers (see the box to the right) Monday through Friday, 8:00 AM - 8:00 PM ET, with any questions regarding our Patient Assistance Program, eligibility requirements, or the application process.

CSL Behring reserves the right, at its sole discretion, to discontinue the Patient Assistance Program at any time. All patient information remains confidential. Product supply for the program depends on availability.

CRP16-05-0001 05/2016
© 2018 CSL Behring